https://www.akineyeonfda.com/en/fda-announces-device-trial-participation-snapshots https://www.akineyeonfda.com/en/fda-approves-the-first-flu-vaccine-for-at-home-use-providing-a-needle-free-option-outside-of-traditional-health-care-settings https://www.akineyeonfda.com/en/fda-announces-draft-guidance-for-industry-regarding-accelerated-approval-for-drugs-and-biologics https://www.akineyeonfda.com/en/fda-finalizes-pccp-guidance-for-ai-enabled-medical-devices https://www.akineyeonfda.com/en/fda-and-department-of-veteran-affairs-set-to-launch-virtual-lab-testing-ai-tools-subject-to-trumps-plans https://www.akineyeonfda.com/en/advamed-releases-ai-white-paper https://www.akineyeonfda.com/en/fda-announces-plan-to-speed-up-public-notification-about-potentially-high-risk-device-recalls https://www.akineyeonfda.com/en/fda-finalizes-guidance-on-communication-of-unapproved-uses-of-approved-or-cleared-medical-products https://www.akineyeonfda.com/en/three-questions-with-sedgwicks-jeremy-schutz https://www.akineyeonfda.com/en/in-waning-days-of-the-current-administration-fda-announces-red-no-3-ban https://www.akineyeonfda.com/en/maha-commission-report-on-childrens-health-takes-aim-at-ultra-processed-foods-and-medication-practices-among-other-targets https://www.akineyeonfda.com/en/fda-issues-key-guidance-updates-for-digital-health-and-wellness https://www.akineyeonfda.com/en/selfcollection-kits-in-the-crosshairs https://www.akineyeonfda.com/en/food-update-or-grasping-the-moment-fda-gras-reform-steps-into-the-spotlight https://www.akineyeonfda.com/en/hhs-kicks-off-rare-disease-week-with-fda-release-of-draft-guidance-on-plausible-mechanism-framework-for-individualized-therapies https://www.akineyeonfda.com/en/fda-continues-focus-on-rare-disease-drug-development-announces-evidence-principles https://www.akineyeonfda.com/en/fda-continues-focus-on-ai-fronts-seeks-public-comment-on-measuring-and-evaluating-ai-enabled-medical-device-performance-in-the-real-world https://www.akineyeonfda.com/en/fdas-tempo-pilot-seeks-to-expand-access-to-chronic-disease-technologies-in-cms-collaboration https://www.akineyeonfda.com/en/fda-puts-orange-b-on-the-chopping-block https://www.akineyeonfda.com/en/fda-presses-forward-on-incorporating-patient-preferences-in-device-decision-making-releases-updated-final-guidance https://www.akineyeonfda.com/en/fda-publishes-a-wide-range-of-guidances-in-the-final-days-of-the-biden-administration https://www.akineyeonfda.com/en/fda-issues-rfi-on-pfas-in-seafood https://www.akineyeonfda.com/en/national-institutes-of-health-develops-ai-algorithm-to-identify-potential-volunteers-for-clinical-trials https://www.akineyeonfda.com/en/fda-publishes-digital-health-and-artificial-intelligence-glossary https://www.akineyeonfda.com/en/is-self-affirming-gras-off-the-menu https://www.akineyeonfda.com/en/hhs-fda-announce-phase-out-of-synthetic-dyes-in-foods-as-maha-agenda-advances https://www.akineyeonfda.com/en/fda-green-lights-another-natural-food-color https://www.akineyeonfda.com/en/from-foods-to-pharmaceuticals-maha-strategy-offers-broad-menu-of-fda-actions https://www.akineyeonfda.com/en/congress-joins-fda-in-focusing-on-food-dye-limitations https://www.akineyeonfda.com/en/citizen-petition-calls-on-fda-to-rethink-refined-carbs https://www.akineyeonfda.com/en/fda-opens-the-vault-on-decision-lettersreleases-wave-of-drug-and-biologic-crls https://www.akineyeonfda.com/en/fda-names-the-first-nine-national-priority-voucher-recipients https://www.akineyeonfda.com/en/fda-precheck-pilot-program-launches-clearing-a-smooth-path-to-approval https://www.akineyeonfda.com/en/qanda-fda-seeks-to-clarify-3-year-exclusivity-with-new-guidance https://www.akineyeonfda.com/en/fda-issues-draft-guidance-for-responses-to-form-483-drug-cgmp-inspections https://www.akineyeonfda.com/en/fda-grants-three-natural-food-additive-petitions https://www.akineyeonfda.com/en/dr-tidmarsh-to-head-cder https://www.akineyeonfda.com/en/fda-moves-forward-on-fluoropolymers https://www.akineyeonfda.com/en/fda-plans-to-phase-out-animal-testing-requirements-for-monoclonal-antibodies-and-other-drugs https://www.akineyeonfda.com/en/fda-unveils-draft-guidance-on-developing-drugs-and-biological-products-for-weight-reduction https://www.akineyeonfda.com/en/just-prior-to-leadership-change-fda-announces-public-workshops-to-advance-dialogues-on-hct-product-development-and-optimizing-pregnancy-registries https://www.akineyeonfda.com/en/fda-amplifies-cross-center-collaboration-with-the-creation-of-the-rare-disease-innovation-hub https://www.akineyeonfda.com/en/fda-authorizes-marketing-for-first-combination-flu-and-covid-19-at-home-test-outside-of-emergency-use https://www.akineyeonfda.com/en/fda-issues-draft-guidance-with-updated-recommendations-for-assessing-the-need-for-comparative-efficacy-studies-in-biosimilar-development https://www.akineyeonfda.com/en/congress-rallies-to-extend-rare-pediatric-disease-priority-review-voucher-program https://www.akineyeonfda.com/en/fda-presses-forward-on-pdufa-vii-cgt-commitments-with-release-of-draft-guidance-on-clinical-trial-design-methods-for-capturing-postapproval-data https://www.akineyeonfda.com/en https://www.akineyeonfda.com/en/district-court-vacates-fda-ldt-rule-whats-next-for-regulation-of-lab-testing https://www.akineyeonfda.com/en/fdas-latest-on-emergency-diagnostics-and-a-no-frills-rescission-of-the-ldt-rule https://www.akineyeonfda.com/en/president-elect-trump-makes-more-hhs-personnel-moves-dr-marty-makary-tapped-to-lead-fda https://www.akineyeonfda.com/en/fda-announces-new-center-for-real-world-evidence-innovation https://www.akineyeonfda.com/en/in-effort-to-avoid-supply-chain-disruptions-fda-extends-dscsa-exemptions https://www.akineyeonfda.com/en/fda-announces-new-director-of-the-center-for-devices-and-radiological-health https://www.akineyeonfda.com/en/fda-announces-draft-guidance-on-accelerated-approval-and-considerations-for-determining-whether-a-confirmatory-trial-is-underway https://www.akineyeonfda.com/en/no-appeal-of-ldt-decision-means-ball-is-back-in-fdas-court-for-policy-clarification https://www.akineyeonfda.com/en/fda-adds-a-dose-of-clarity-to-the-ndin-process https://www.akineyeonfda.com/en/hhs-to-launch-campaign-promoting-wearable-devices https://www.akineyeonfda.com/en/fda-announces-public-hearing-and-opportunity-to-comment-on-national-priority-voucher-pilot-program https://www.akineyeonfda.com/en/fdas-new-communications-and-compliance-tool-for-device-data-integrity-concerns https://www.akineyeonfda.com/en/hhs-fda-announce-multiple-initiatives-on-food-safety-quality-and-compliance-fronts https://www.akineyeonfda.com/en/fdas-idea-lab-seeks-to-reimagine-device-use-in-the-home-through-new-virtual-reality-prototype https://www.akineyeonfda.com/en/fda-and-hhs-appoint-ai-chiefs https://www.akineyeonfda.com/en/five-fda-takeaways-from-the-fy26-budget https://www.akineyeonfda.com/en/fda-hhs-and-usda-serve-up-ultra-processed-food-rfi https://www.akineyeonfda.com/en/fda-announces-ai-councils-amid-calls-for-greater-agency-transparency https://www.akineyeonfda.com/en/fda-announces-commissioners-national-priority-voucher-program-to-accelerate-drug-application-review-process-and-support-national-priorities https://www.akineyeonfda.com/en/fda-presses-forward-on-patient-focused-drug-development-releases-final-guidance-focused-on-fit-for-purpose-clinical-outcome-assessments https://www.akineyeonfda.com/en/fda-releases-final-guidance-on-best-practices-for-bioresearch-monitoring-inspections https://www.akineyeonfda.com/en/fda-and-nih-take-actions-to-reduce-reliance-on-animal-testing-with-new-draft-guidance-and-funding-announcement